This page lists the SEC filings reported by Lincoln Park Capital Fund, LLC.
| Type | Filed | Filer | Subject | Shares Owned | Percent Owned | |
|---|---|---|---|---|---|---|
| SC 13G/A | 2024-02-14 | Lincoln Park Capital Fund, LLC | Cellectar Biosciences, Inc. | 1,307,049 | 9.7% | EDGAR |
| SC 13G/A | 2024-02-14 | Lincoln Park Capital Fund, LLC | WINDTREE THERAPEUTICS INC /DE/ | 339,167 | 6.2% | EDGAR |
| SC 13G/A | 2024-02-14 | Lincoln Park Capital Fund, LLC | Ensysce Biosciences, Inc. | 124,008 | 3.8% | EDGAR |
| SC 13G/A | 2024-02-14 | Lincoln Park Capital Fund, LLC | Tracon Pharmaceuticals, Inc. | 116,821 | 0.4% | EDGAR |
| SC 13G/A | 2024-02-14 | Lincoln Park Capital Fund, LLC | X4 Pharmaceuticals, Inc | 1,600,136 | 0.9% | EDGAR |
| SC 13G/A | 2024-02-14 | Lincoln Park Capital Fund, LLC | KIORA PHARMACEUTICALS INC | 768,155 | 10.0% | EDGAR |
| SC 13G | 2023-06-02 | Lincoln Park Capital Fund, LLC | Tracon Pharmaceuticals, Inc. | 2,369,821 | 9.0% | EDGAR |
| SC 13G | 2023-04-24 | Lincoln Park Capital Fund, LLC | WINDTREE THERAPEUTICS INC /DE/ | 459,042 | 10.0% | EDGAR |
| SC 13G | 2023-02-07 | Lincoln Park Capital Fund, LLC | Ensysce Biosciences, Inc. | 1,501,055 | 10.0% | EDGAR |
| SC 13G | 2022-10-25 | Lincoln Park Capital Fund, LLC | Cellectar Biosciences, Inc. | 937,588 | 10.0% | EDGAR |
| SC 13G | 2022-07-28 | Lincoln Park Capital Fund, LLC | KIORA PHARMACEUTICALS INC | 3,280,476 | 10.0% | EDGAR |
| SC 13G | 2022-05-18 | Lincoln Park Capital Fund, LLC | Vallon Pharmaceuticals, Inc. | 1,050,232 | 10.0% | EDGAR |
| SC 13G | 2022-04-27 | Lincoln Park Capital Fund, LLC | Salarius Pharmaceuticals, Inc. | 2,969,718 | 6.0% | EDGAR |
| SC 13G | 2022-01-19 | Lincoln Park Capital Fund, LLC | X4 Pharmaceuticals, Inc | 1,810,087 | 6.4% | EDGAR |
| SC 13G | 2021-11-19 | Lincoln Park Capital Fund, LLC | Nabriva Therapeutics plc | 4,512,589 | 8.0% | EDGAR |
| SC 13G | 2021-04-28 | Lincoln Park Capital Fund, LLC | Benitec Biopharma Inc. | 423,529 | 5.4% | EDGAR |
| SC 13G | 2021-01-19 | Lincoln Park Capital Fund, LLC | VIVEVE MEDICAL, INC. | 701,000 | 10.0% | EDGAR |
| SC 13G | 2021-01-08 | Lincoln Park Capital Fund, LLC | Onconova Therapeutics, Inc. | 13,639,411 | 6.5% | EDGAR |
| SC 13G | 2020-11-13 | Lincoln Park Capital Fund, LLC | Moleculin Biotech, Inc. | 4,787,254 | 7.5% | EDGAR |
| SC 13G | 2020-08-03 | Lincoln Park Capital Fund, LLC | Advaxis, Inc. | 4,594,793 | 6.9% | EDGAR |
- Form 13F-HR
- The 13F-HR report is filed quarterly to report securities held by the filer that fall under the SEC's 13F rules.
- Form SC 13D/G
- Reported by persons and groups who own 5% or more of any class of a company's outstanding shares. If the ownership changes by 1% or more, an amendment must be filed.
- Form 3, 4, and 5
- Form 3, 4, and 5 reports are filed to report insider transactions by company officers and directors, and any beneficial owners of more than ten percent of a company's shares. Form 3 is the initial report that must be filed when a person becomes an officer, director, or beneficial owner. Form 4 reports are used to report changes in ownership, while the Form 5 report is used for reporting transactions that should have been reported earlier in a Form 4 filing.